Last update Jan. 21, 2021
Limited compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
C16H17ClN2O is Tetrazepam in Molecular formula.
Is written in other languages:Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 80 - 100 | % |
Molecular weight | 289 | daltons |
Protein Binding | 95 | % |
VD | 3 - 7 | l/Kg |
Tmax | 0.5 - 1.5 | hours |
T½ | 15 - 25 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Intermediate-acting benzodiazepine.
It was marketed in several countries as a muscle relaxant.
Oral administration once or twice daily doses.
At latest update no published data on excretion into breast milk were found.
Its pharmacokinetic data (large volume of distribution and high percentage of protein binding) makes transfer into breastmilk in significant quantities unlikely.
It has very few bibliographical references, and is marketed in few countries.
Withdrawal from the European market due to serious side effects (Proy-Vega 2014 y 2013, Portalfarma 2013, EMA 2013).
The occasional use and low doses of benzodiazepines are compatible with breastfeeding (Kelly 2012, Rubin 2004, Iqbal 2002, Hägg 2000, McElhatton 1994, Lee 1993, Kanto 1982).
It is advisable to choose a short-acting benzodiazepine and minimal effective dose as possible (Rowe 2013), especially in the neonatal period and in case of prematurity because they can accumulate in the infant during chronic use (Sachs 2013).
It is advisable to monitor drowsiness and adequate feeding of the infant.
It is not recommended to share a bed (co-sleeping, bed-sharing) with the baby if this drug is being taken, due to increased risk of asphyxia or sudden infant death (UNICEF 2018, 2017, 2014 and 2013, Landa 2012, ABM 2008, UNICEF 2006).